Literature DB >> 1253395

The effects of delta-9-tetrahydrocannabinol (cannabis) on cardiac performance with and without beta blockade.

C Kanakis, J M Pouget, K M Rosen.   

Abstract

Systolic time intervals (STI) were measured in ten healthy male volunteers before and after intravenous (i.v.) administration of 25 mug/kg delta-9-tetrahydrocannabinol (delta-9-THC). Mean +/- SEM heart rate increased 32 +/- 7 beats/min, while systolic and diastolic blood pressures were unchanged after delta-9-THC. Total electromechanical systole lengthened 17 +/- 4.2 msec, left ventricular ejection time (LVETc) prolonged 24 +/- 4.0 msec and pre-ejection period (PEP) shortened 17 +/- 5.1 msec after delta-9-THC. All of these changes were significant (P less than 0.01). In nine other subjects who underwent prior beta adrenergic blockade, similar but less marked changes were noted in heart rate, blood pressure, and STI after delta-9-THC. The shortening of PEP after delta-9-THC was only 9 msec (NS) in beta blocked subjects. Thus, delta-9-THC significantly increased heart rate, shortened PEP and prolonged LVETc without any change in afterload. Beta adrenergic blockade prevented significant shortening of PEP and blunted other responses. These findings suggest that delta-9-THC enhanced cardiac performance. Partial inhibition of this effect was achieved with prior beta adrenergic blockade.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1253395     DOI: 10.1161/01.cir.53.4.703

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  19 in total

Review 1.  Recreational drug misuse: issues for the cardiologist.

Authors:  A Ghuran; J Nolan
Journal:  Heart       Date:  2000-06       Impact factor: 5.994

2.  Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors.

Authors:  Sándor Bátkai; Pál Pacher; Zoltán Járai; Jens A Wagner; George Kunos
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-04-01       Impact factor: 4.733

3.  Safety of oral dronabinol during opioid withdrawal in humans.

Authors:  Crystal J Jicha; Michelle R Lofwall; Paul A Nuzzo; Shanna Babalonis; Samy Claude Elayi; Sharon L Walsh
Journal:  Drug Alcohol Depend       Date:  2015-10-09       Impact factor: 4.492

4.  Cannabis and the cardiovascular system.

Authors: 
Journal:  Br Med J       Date:  1978-02-25

Review 5.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

Review 6.  Cardiovascular pharmacology of cannabinoids.

Authors:  P Pacher; S Bátkai; G Kunos
Journal:  Handb Exp Pharmacol       Date:  2005

7.  Effects of delta1-trans-tetrahydrocannabinol on mechanical performance of isolated heart muscle preparations.

Authors:  J D Graham; A C Grey; A H Henderson; M J Lewis
Journal:  Br J Pharmacol       Date:  1978-01       Impact factor: 8.739

8.  Rimonabant: the role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients.

Authors:  Christopher T Dibble; Eli V Gelfand; Christopher P Cannon
Journal:  Curr Atheroscler Rep       Date:  2007-11       Impact factor: 5.113

9.  Recurrent STEMI Precipitated by Marijuana Use: Case Report and Literature Review.

Authors:  Perry Wengrofsky; Ghassan Mubarak; Ahmed Shim; Pramod Theetha Kariyanna; Adam Buzidkowski; Jacob Schwartz; Samy I McFarlane
Journal:  Am J Med Case Rep       Date:  2018

10.  Intermediate cannabis dependence phenotypes and the FAAH C385A variant: an exploratory analysis.

Authors:  Joseph P Schacht; Rebecca E Selling; Kent E Hutchison
Journal:  Psychopharmacology (Berl)       Date:  2008-11-12       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.